![Charles Fuchs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Charles Fuchs
Technik-/Wissenschafts-/F&E-Leiter bei
ERASCA, INC.
Vermögen: - $ am 31.08.2026
Profil
Charles S.
Fuchs is currently the Director at the Association of American Cancer Institutes since 2020, Director at CytomX Therapeutics, Inc. starting in 2026, and President-Research & Development at Erasca, Inc. starting in 2026.
Former positions include Independent Director at CytomX Therapeutics, Inc., Director at Yale Cancer Center from 2017 to 2021, Professor at Harvard Medical School, and Chief Medical Officer at Tubulis GmbH from 2025 to 2026.
Education includes a doctorate from Harvard Medical School conferred in 1986 and a doctorate from Harvard T.H.
Chan School of Public Health conferred in 1994.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.07.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
Aktive Positionen von Charles Fuchs
| Unternehmen | Position | Beginn |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.07.2026 |
| ERASCA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.08.2026 |
Association of American Cancer Institutes
 Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Operates as a membership association and cancer research center | Direktor/Vorstandsmitglied | 29.06.2020 |
Ehemalige bekannte Positionen von Charles Fuchs
| Unternehmen | Position | Ende |
|---|---|---|
Tubulis GmbH
 Tubulis GmbH BiotechnologyHealth Technology Develops and manufactures antibody-drug conjugates with biophysical properties to treat cancer tumors | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2026 |
Yale Cancer Center
 Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Direktor/Vorstandsmitglied | 01.02.2021 |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| CYTOMX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Charles Fuchs
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
67
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Health Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Association of American Cancer Institutes
Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Operates as a membership association and cancer research center | Commercial Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Tubulis GmbH
Tubulis GmbH BiotechnologyHealth Technology Develops and manufactures antibody-drug conjugates with biophysical properties to treat cancer tumors | Health Technology |
